BioCentury
ARTICLE | Product Development

RA readout drives Aclaris’ first big gain since shifting focus to innovative immunology pipeline

January 20, 2021 1:58 AM UTC

An efficacy readout in a small Phase IIa trial of Aclaris’ oral therapy for rheumatoid arthritis has more than tripled the company’s market cap, representing its first major value-creating event since it restructured in 2H19 to focus on immunology programs obtained in a deal.

Aclaris Therapeutics Inc. (NASDAQ:ACRS) climbed $12.95 (220%) to $18.83 Tuesday, touching an intraday two-year high of $19.95, after reporting that its MK2 inhibitor ATI-450 led to reductions in disease severity scores in the RA-201 trial. The 19-patient, placebo-controlled study was not powered for statistical significance...